TY - JOUR
T1 - Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content
AU - Krul, E. S.
AU - Lemke, S. L.
AU - Mukherjea, R.
AU - Taylor, M. L.
AU - Goldstein, D. A.
AU - Su, H.
AU - Liu, P.
AU - Lawless, A.
AU - Harris, W. S.
AU - Maki, K. C.
N1 - Funding Information:
This trial was funded by Solae LLC, St. Louis, MO and Monsanto Company.
PY - 2012/1
Y1 - 2012/1
N2 - Objective: The purpose of this randomized, controlled, parallel group study was to characterize the relationships between dosages of stearidonic acid (SDA) and eicosapentaenoic acid (EPA), and incorporation of EPA into red blood cell (RBC) membranes over time. Methods: Healthy subjects (n=131) received capsules with placebo (safflower oil), SDA (0.43, 1.3, 2.6, or 5.2. g/d) or EPA (0.44, 1.3, or 2.7. g/d) for 12 weeks. RBC fatty acids were analyzed biweekly. Results: RBC %EPA increased in all EPA and SDA groups (p<0.02 vs. control) except the 0.43. g/d SDA group (p=0.187). For theoretical intakes of EPA of 0.25, 0.5, and 0.89. g/d, the amounts of SDA needed to achieve equivalent RBC EPA enrichment were 0.61, 1.89, and 5.32. g/d (conversion efficiencies of 41%, 26%, and 17%), respectively. Conclusions: SDA increased RBC %EPA in a dosage and time-dependent manner at intakes as low as 1.3. g/d.
AB - Objective: The purpose of this randomized, controlled, parallel group study was to characterize the relationships between dosages of stearidonic acid (SDA) and eicosapentaenoic acid (EPA), and incorporation of EPA into red blood cell (RBC) membranes over time. Methods: Healthy subjects (n=131) received capsules with placebo (safflower oil), SDA (0.43, 1.3, 2.6, or 5.2. g/d) or EPA (0.44, 1.3, or 2.7. g/d) for 12 weeks. RBC fatty acids were analyzed biweekly. Results: RBC %EPA increased in all EPA and SDA groups (p<0.02 vs. control) except the 0.43. g/d SDA group (p=0.187). For theoretical intakes of EPA of 0.25, 0.5, and 0.89. g/d, the amounts of SDA needed to achieve equivalent RBC EPA enrichment were 0.61, 1.89, and 5.32. g/d (conversion efficiencies of 41%, 26%, and 17%), respectively. Conclusions: SDA increased RBC %EPA in a dosage and time-dependent manner at intakes as low as 1.3. g/d.
KW - Dosage-response
KW - Eicosapentaenoic acid
KW - Omega-3 fatty acids
KW - RBC
KW - Stearidonic acid
UR - http://www.scopus.com/inward/record.url?scp=84155162472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84155162472&partnerID=8YFLogxK
U2 - 10.1016/j.plefa.2011.10.005
DO - 10.1016/j.plefa.2011.10.005
M3 - Article
C2 - 22064208
AN - SCOPUS:84155162472
SN - 0952-3278
VL - 86
SP - 51
EP - 59
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
IS - 1-2
ER -